Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a report released on Friday morning, Benzinga reports.

Several other equities analysts have also recently issued reports on AGIO. JPMorgan Chase & Co. reiterated a neutral rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. Royal Bank of Canada reiterated an outperform rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday. StockNews.com cut Agios Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, August 5th. Finally, The Goldman Sachs Group lifted their price target on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a neutral rating in a research report on Tuesday, June 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Hold and a consensus target price of $51.33.

Agios Pharmaceuticals Trading Down 1.8 %

Agios Pharmaceuticals stock opened at $46.55 on Friday. Agios Pharmaceuticals has a 52 week low of $19.80 and a 52 week high of $50.35. The stock has a market cap of $2.64 billion, a price-to-earnings ratio of -7.37 and a beta of 0.75. The company’s 50-day moving average price is $45.69 and its two-hundred day moving average price is $39.03.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. Agios Pharmaceuticals’s revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.51) EPS. Research analysts expect that Agios Pharmaceuticals will post -4.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the transaction, the chief executive officer now directly owns 78,792 shares in the company, valued at approximately $3,368,358. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Farallon Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 1.1% in the 2nd quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock worth $243,822,000 after acquiring an additional 63,900 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Agios Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock worth $162,926,000 after buying an additional 44,583 shares during the period. Armistice Capital LLC boosted its position in shares of Agios Pharmaceuticals by 6.0% in the fourth quarter. Armistice Capital LLC now owns 3,524,000 shares of the biopharmaceutical company’s stock worth $78,479,000 after buying an additional 200,000 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Agios Pharmaceuticals by 5.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,596,764 shares of the biopharmaceutical company’s stock worth $57,832,000 after buying an additional 137,873 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Agios Pharmaceuticals by 23.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after buying an additional 388,381 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.